Zhejiang Yatai Pharmaceutical Co., Ltd. researches, produces, sells, and exports pharmaceutical products in China and internationally. The company offers solid...
After two consecutive setbacks, Yatai Pharm accelerates its strategic transformation in the innovative drug industry
Yatai Pharm: The cumulative deviation of the stock price increase over the past two days exceeds 20%, warning of risks
A-share innovative drug concept stocks are active again, Sunshine Guojian Pharmaceutical rose over 10% to a new high, Yatai Pharm had two consecutive limit-ups, WECOME rose over 10%, and Baicheng Pharmaceutical, ALK, and Fushine followed suit
Yatai Pharm released its performance for the first three quarters, with a net profit attributable to the parent company of 97.195 million yuan, a year-on-year increase of 2909.49%
The actual controller of Yatai Pharm will change to Qiu Zhongxun, and trading will resume on October 14
Yatai Pharm: Signed a share transfer agreement, control rights are expected to change